Evidence map›Paper›PMID 31717978›Full record

ArticleCancers2019

Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia.

Eleonora Mäkelä, Eliisa Löyttyniemi, Urpu Salmenniemi, Otto Kauko, Taru Varila, Veli Kairisto, Maija Itälä-Remes, Jukka Westermarck

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Eleonora MäkeläTurku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
Eliisa LöyttyniemiDepartment of Biostatistics, University of Turku, 20520 Turku, Finland.
Urpu SalmenniemiDepartment of Hematology, Turku University Hospital (TYKS), 20521 Turku, Finland.
Otto KaukoTurku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
Taru VarilaTurku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
Veli KairistoCentral Laboratory, Turku University Hospital (TYKS), 20521 Turku, Finland.
Maija Itälä-RemesDepartment of Hematology, Turku University Hospital (TYKS), 20521 Turku, Finland.
Jukka WestermarckTurku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.ORCID 0000-0001-7478-3018
Åbo Akademi University · FITurku University Hospital · FIUniversity of Turku · FI

Funding

Business Finland TUTL 2445/31/2017Kalevi Soininen Foundation naThe Sigrid Jusélius Foundation naTurku University Hospital ERVA 13283
6 · The paper itself

Abstract

Disease relapse from standard chemotherapy in acute myeloid leukemia (AML) is poorly understood. The importance of protein phosphatase 2A (PP2A) as an AML tumor suppressor is emerging. Therefore, here, we examined the potential role of endogenous PP2A inhibitor proteins as biomarkers predicting AML relapse in a standard patient population by using three independent patient materials: cohort1 (

Indexed as

ARPP-19cancerMRDPME-1SETWT1

Identifiers

PMID31717978
PMCPMC6895887
OpenAlexW2986809356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.